Drug Trial Radar · NCT05850234
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
232
Planned (sponsor's estimate)
Start
Jul 20, 2023
Primary completion
Oct 1, 2027
Study completion Jan 25, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
AZD0120Biological
AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Adverse Events (AEs)Time frame: Through study completion, a minimum of 2 years.
- Phase 1b: Dose-Limiting Toxicities (DLTs)Time frame: 28 days
- Phase 2: Objective Response Rate (ORR)Time frame: Through study completion, a minimum of 2 years.
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
Denver, Colorado · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Iowa City, Iowa · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Minneapolis, Minnesota · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Omaha, Nebraska · Withdrawn
Research Site
Hackensack, New Jersey · Withdrawn
Research Site
Buffalo, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
Stony Brook, New York · Recruiting
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Durham, North Carolina · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Austin, Texas · Recruiting
Research Site
Dallas, Texas · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Salt Lake City, Utah · Recruiting
Research Site
Charlottesville, Virginia · Recruiting
Research Site
Edmonds, Washington · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.